Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytomegalovirus pp65–IE1 Fusion Protein
- Molecular classification
- Fusion Protein, Viral Antigen
01
Overview
The cytomegalovirus (CMV) pp65–IE1 fusion protein is a synthetic or recombinant antigen that combines two major immunodominant proteins from human cytomegalovirus (HCMV): phosphoprotein 65 (pp65, also known as UL83) and immediate early protein 1 (IE1). Both proteins are principal targets of the cellular immune response in HCMV infection, making their fusion a promising candidate for vaccine development and T cell-based immunotherapies. It is designed to induce broad antiviral T-cell response; modulates host immunity. Used as a vaccine candidate and in adoptive immunotherapy.
- Other names
- pp65–IE1 Fusion Proteinpp65-IE1UL83-IE1 Fusion Protein
02
Mechanism of action
Induces T-cell mediated immune response against CMV.
03
Biological functions
Antigen presentationT-cell activationImmune response inductionModulation of host immunity
04
Disease associations
Cytomegalovirus infection
05
Safety considerations
Potential for off-target effects of T-cell therapiesRisk associated with viral vector delivery (if used)
Beyond the preview
Go deeper on Cytomegalovirus pp65–IE1 Fusion Protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytomegalovirus pp65–IE1 Fusion Protein.